Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 9, 2023
Discovery & Translation

Two metabolites that inhibit Th17 differentiation for MS; plus Cirius’ MPC inhibitor for COVID-19 and more

BioCentury’s roundup of translational news
BioCentury | Dec 7, 2022
Product Development

Dec. 6 Quick Takes: Gossamer falls on PAH data

Plus: HotSpot, AbbVie in IRF5 collaboration and updates from Leo, MorphoSys-Novartis, Pfizer-Clear Creek  
BioCentury | Apr 20, 2022
Data Byte

Colitis innovation in the Distillery spotlight

Targets include LRH-1, PYK2, BDNF, HSF1, ZDHHC7, LYPLA2 and cGas
BioCentury | Jan 7, 2022
Distillery Therapeutics

Inhibiting the PYK2-IRF5 axis for ulcerative colitis

BioCentury | Dec 2, 2021
Finance

Dec. 1 Quick Takes: New round pushes Abogen’s venture haul over $1B

Plus Hotspot, Apollo, Curie, ICER, Zogenix, Chinook, BeyondSpring
BioCentury | Aug 27, 2021
Distillery Therapeutics

Inhibiting IRF5 to treat lupus

BioCentury | May 28, 2015
Distillery Therapeutics

Therapeutics: Interferon regulatory factor 5 (IRF5)

Items per page:
1 - 8 of 8